Imprimis Pharmaceuticals Inc (IMMY) was Initiated by Rodman & Renshaw to “Buy” and the brokerage firm has set the Price Target at $5. Rodman & Renshaw advised their investors in a research report released on Nov 28, 2016.
Imprimis Pharmaceuticals Inc opened for trading at $2.561 and hit $2.72 on the upside on Friday, eventually ending the session at $2.61, with a gain of 1.95% or 0.05 points. The heightened volatility saw the trading volume jump to 18,839 shares. Company has a market cap of $35 M.
Imprimis Pharmaceuticals Inc. (Imprimis) is a pharmaceutical company. The Company focuses on developing and commercializing compounded drug therapies and making these therapies available to physicians and patients. It owns markets and sells a portfolio of combination formulations in ophthalmology and urology. Its ophthalmology formulation portfolio includes Dropless Therapy and LessDrops formulations which serve the eye drop market. Its Defeat IC campaign includes a compounded formulation for patients suffering from interstitial cystitis. It makes dispenses and sells its compounded formulations as well as other non-proprietary products through its compounding pharmacies Pharmacy Creations LLC (Pharmacy Creations) and Park. Its pharmacies also dispense prescriptions for complementary compounded formulations within the ophthalmology and urology therapeutic areas as well as other compounded formulations in other therapeutic areas for an individually identified patient.